India Approves First-Ever Dengue Vaccine | QDENGA Gets Green Signal

[00:00:00]Major breakthrough in India's fight against dengue. The country has approved its first ever dengue vaccine. In a significant boost to public health, Japan's Takeda Pharmaceuticals has received regulatory approval for Qdenga.

[00:00:16]India has taken this landmark step in the battle against dengue with the country's drug regulator approving Takeda Pharmaceuticals' Qdenga, making it the first dengue vaccine to receive approval in India.

[00:00:30]The vaccine is a tetravalent live attenuated vaccine, meaning it is designed to protect against all four dengue virus serotypes.

[00:00:43]A key advantage, it can be administered regardless of whether a person has previously had dengue or not, and it does not require pre-vaccination testing, making it easier to roll out on a large scale. The approval comes at a crucial time as dengue cases in India have surged dramatically. According to Takeda Pharmaceuticals, reported dengue infections uh have increased 11-fold over the past two decades, highlighting the urgent need for stronger preventive measures.

[00:01:15]India carries nearly 1/3 of the world's dengue burden, making the vaccine's approval a significant public health milestone.

[00:01:24]Takeda has also strengthened its manufacturing plans for India.

[00:01:30]In 2024, the Japanese pharmaceutical giant partnered with the Indian vaccine manufacturer Biological to expand production capacity. Under the agreement, Biological E aims to manufacture 50 million doses every year, supporting Takeda's global target of producing 100 million doses annually by the end of this decade.

[00:01:52]Qdenga is already being used across the world. Since its launch in 2022. The vaccine has received approval in 43 countries with more than 32 million doses distributed globally already.

[00:02:06]According to Takeda Pharmaceuticals, long-term clinical data shows that Qdenga provides sustained protection against dengue infection and significantly reduces the risk of dengue-related hospitalization.

[00:02:18]With dengue continuing to pose a major seasonal health challenge across India, the approval of Qdenga could mark a new chapter in reducing severe infections, saving lives, and strengthening the country's fight against one of its most persistent mosquito-borne diseases.

[00:02:47]Major breakthrough in India's fight against dengue. The country has approved its first-ever dengue vaccine. In a significant boost to public health, Japan's Takeda Pharmaceuticals has received regulatory approval for Qdenga.

[00:03:04]India has taken this landmark step in the battle against dengue with the country's drug regulator approving Takeda Pharmaceuticals' Qdenga, making it the first dengue vaccine to receive approval in India.

[00:03:18]The vaccine is a tetravalent live attenuated vaccine, meaning it is designed to protect against all four dengue virus serotypes.

[00:03:31]A key advantage, it can be administered regardless of whether a person has previously had dengue or not, and it does not require pre-vaccination testing, making it easier to roll out on a large scale. The approval comes at a crucial time as dengue cases in India have surged dramatically. According to Takeda Pharmaceuticals, reported dengue infections uh have increased 11-fold over the past two decades.

[00:03:59]Highlighting the urgent need for stronger preventive measures.

[00:04:03]India carries nearly 1/3 of the world's dengue burden, making the vaccine's approval a significant public health milestone.

[00:04:12]Takeda has also strengthened its manufacturing plans for India.

[00:04:18]In 2024, the Japanese pharmaceutical giant partnered with the Indian vaccine manufacturer Biological to expand production capacity. Under the agreement, Biological E aims to manufacture 50 million doses every year, supporting Takeda's global target of producing 100 million doses annually by the end of this decade.

[00:04:40]QDENGA is already being used across the world.

[00:04:44]Since its launch in 2022, the vaccine has received approval in 43 countries, with more than 32 million doses distributed globally already.

[00:04:54]According to Takeda Pharmaceuticals, long-term clinical data shows that QDENGA provides sustained protection against dengue infection and significantly reduces the risk of dengue-related hospitalization.

[00:05:06]With dengue continuing to pose a major seasonal health challenge across India, the approval of QDENGA could mark a new chapter in reducing severe infections, saving lives, and strengthening the country's fight against one of its most persistent mosquito-borne diseases.